Take a look at a CIDP treatment that’s designed differently

VYVGART Hytrulo works differently than treatments like IVIg, SCIg, PLEX, and steroids.

CIDP=chronic inflammatory demyelinating polyneuropathy;
IVIg=intravenous immunoglobulin; PLEX=plasma exchange; SCIg=subcutaneous immunoglobulin

The first major innovation in CIDP treatment in over 30 years*

The complete cause of chronic inflammatory demyelinating polyneuropathy (CIDP) is not fully understood. Recent studies suggest that in some people, harmful antibodies like the harmful IgG, may be involved in damaging myelin. VYVGART Hytrulo is specifically designed to cause a reduction in the number of IgG antibodies, including harmful IgG antibodies.

*VYVGART Hytrulo contains efgartigimod alfa and hyaluronidase, and is specifically designed to attach to FcRn receptors.
FcRn=neonatal Fc receptor; IgG=immunoglobulin G

The science behind VYVGART Hytrulo made simple and fun

The science of CIDP can get complex, but this video breaks it down simply. Travel into the body to see how CIDP works and get a better understanding of the science behind VYVGART Hytrulo.

Meet the cast

Your body has many “characters” that influence how information travels to and from the brain and the rest of your body. Expand below to learn more about some of the possible characters that may play a role in CIDP and treatment with VYVGART Hytrulo.

Helpful IgG antibody

Immunoglobulin G (IgG) antibody is a Y-shaped protein made by the immune system. Antibodies—like IgG—play a vital role in helping protect your body from infection and disease.

Harmful IgG antibody

Harmful IgG antibody is a Y-shaped protein mistakenly made by the immune system that attacks the body. In some people with CIDP, harmful IgG—along with other characters—may be involved in causing damage to the myelin that covers the nerves.

FcRn receptor

Neonatal Fc receptor (FcRn) is a receptor that IgG antibodies attach to. It helps the IgG antibodies stay in the body longer.

Myelin

A protective coating around nerves that helps messages travel efficiently, establishing a two-way line of communication between the brain and the body. Damage to the myelin over time makes it harder for signals to travel quickly along the nerve or can even stop them completely.

VYVGART Hytrulo

VYVGART Hytrulo (shown in purple) contains efgartigimod alfa and hyaluronidase, and is specifically designed to attach to FcRn receptors.

Hyaluronidase

Hyaluronidase is one of the active ingredients in VYVGART Hytrulo that helps to increase the distribution and absorption of ingredients into the body.

MOA MOA MOA

Take a closer look at VYVGART Hytrulo

VYVGART Hytrulo is a fragment of an IgG antibody designed to form a strong bond with FcRn receptors. By keeping some FcRn receptors occupied, more IgG antibodies, including the harmful type, remain unattached and are then destroyed and removed.

Learn more about CIDP and VYVGART Hytrulo from an expert.

VYVGART Hytrulo has 2 active ingredients: efgartigimod alfa and hyaluronidase (human recombinant).

discussion guide image discussion guide image discussion guide image

You’re the main character—make the most of your next conversation

The CIDP Doctor Discussion Guide is an easy-to-use tool that can help you track your CIDP symptoms and abilities. Providing a better understanding of your daily life with CIDP may help your doctor determine if VYVGART Hytrulo is right for you.

DOWNLOAD THE
DISCUSSION GUIDE

Understand more about VYVGART Hytrulo

VYVGART Hytrulo study results

See the safety and effectiveness results from the largest clinical study in CIDP history.

View the results

About VYVGART Hytrulo injections

A first for CIDP—one subcutaneous injection given weekly that takes ~30 to 90 seconds.*

*After administering your injection, your healthcare provider will monitor you for allergic reactions for at least 30 minutes.

Read more about injections
Live VYVIDLY Logo
Live VYVIDLY Logo

Have questions? Call 1-833-VYV-CIDP (1-833-898-2437) to speak with an educator about CIDP, how VYVGART Hytrulo works, study data, cost and coverage, and more.

Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

VYVGART HYTRULO may cause serious side effects, including:

  • Infection. VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
  • Allergic Reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.
  • Infusion-Related Reactions. VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Before taking VYVGART HYTRULO, tell your doctor if you:

  • take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
  • have received or are scheduled to receive a vaccine (immunization), or
  • have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

What are the common side effects of VYVGART HYTRULO?

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Please see the full Prescribing Information for VYVGART HYTRULO and talk to your doctor.

Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

VYVGART HYTRULO may cause serious side effects, including:

  • Infection. VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
  • Allergic Reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.
  • Infusion-Related Reactions. VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Before taking VYVGART HYTRULO, tell your doctor if you:

  • take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
  • have received or are scheduled to receive a vaccine (immunization), or
  • have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

What are the common side effects of VYVGART HYTRULO?

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Please see the full Prescribing Information for VYVGART HYTRULO and talk to your doctor.

Questions? Call 1-833-VYV-CIDP
(1-833-898-2437)

This site is intended for patients and caregivers.

Disclaimer | Privacy Policy | Contact Us | Prescribing Information

VYVGART is a registered trademark of argenx.

VYVGART Hytrulo is a trademark of argenx.

LIVE VYVIDLY is a trademark of argenx.

LIVING VYVIDLY is a trademark of argenx.

For U.S. audiences only.

©2024 argenx 

US-VYV_HYT-24-00514 V1 12/2024

argenx logo